MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant recipients

被引:67
作者
Bonhomme-Faivre, L
Devocelle, A
Saliba, F
Chatled, S
Maccario, J
Farinotti, R
Picard, V
机构
[1] Hop Paul Brousse, Serv Pharm Pharmacol, F-94800 Villejuif, France
[2] Univ Paris 11, Fac Pharm, UPRES 2706, F-92290 Chatenay Malabry, France
[3] Hop Paul Brousse, Ctr Hepato Biliaire, Villejuif, France
[4] Fac Pharm Paris XI, Dept Biomath, Chatenay Malabry, France
关键词
P-glycoprotein; cyclosporine A; MDR1; polymorphism; liver transplantation; C-2; monitoring;
D O I
10.1097/01.TP.0000130981.55654.78
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Cyclosporine A (CsA) is characterized by high interindividual variations in oral bioavailability and a narrow therapeutic index. CsA is a substrate for P-glycoprotein, a member of the ABC transporter family, ncoded by the multiple drug-resistant gene MDR1. Methods. Because MDR1 gene exon 26 C3435T polymorphism influences intestinal P-glycoprotein expression, we investigated whether this polymorphism was correlated with variation in CsA dose requirement and concentration/ dose ratio in 44 liver-transplant recipients during 1 month, after, transplantation. CsA concentration was measured 2 hours' after administration, (C-2), according to international recommendations. Results. The MDR-1 wild-type genotype (3435CC) was observed in 15 patients (34%), whereas 21 (48%) patients were heterozygous (3435CT), and 8 (18%) patients were homozygous for the mutation (3435TT). There was no significant difference between,the three groups regarding corticosteroids treatment or renal function during this period. One to 3 days after liver transplantation, when every patient received a similar CsA weight-adjusted dose, the concentration/dose ratio was correlated with exon 26 single nucleotide polymorphism and was significantly higher in subjects homozygous for the mutation (P = 0.012). This was confirmed 1 month after transplantation (P = 0.049), when the dose was adjusted to maintain the. C-2 target level of 1,000 mug/L and we observed that TT patients required approximately 50% lower weight-adjusted CsA dose than wild-type patients (P=0,0333). Conclusions. These findings demonstrate that the MDR1 exon 26 C3435T polymorphism is a major determinant of CsA-concentration/dose ratio in liver-transplant recipients and is predictive of the dose of CsA to be administered to achieve the target C-2 concentration.
引用
收藏
页码:21 / 25
页数:5
相关论文
共 19 条
[1]   Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients [J].
Anglicheau, D ;
Verstuyft, CL ;
Laurent-Puig, P ;
Becquemont, L ;
Schlageter, MH ;
Cassinat, B ;
Beaune, P ;
Legendre, C ;
Thervet, E .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (07) :1889-1896
[2]   Frequency distribution of C3435T mutation in exon 26 of the MDR1 gene in a Spanish population [J].
Bernal, ML ;
Sinues, B ;
Fanlo, A ;
Mayayo, E .
THERAPEUTIC DRUG MONITORING, 2003, 25 (01) :107-111
[3]   Recommendations for the implementation of Neoral C2 monitoring in clinical practice [J].
Cole, E ;
Midtvedt, K ;
Johnston, A ;
Pattison, J ;
O'Grady, C .
TRANSPLANTATION, 2002, 73 (09) :S19-S22
[4]  
Demetris A, 2000, Hepatology, V31, P792
[5]   Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects [J].
Evans, WE ;
McLeod, HL .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :538-549
[6]   MDR1 gene expression in peripheral blood mononuclear cells after liver transplantation [J].
Grudé, P ;
Boleslawski, E ;
Conti, F ;
Chouzenoux, S ;
Calmus, Y .
TRANSPLANTATION, 2002, 73 (11) :1824-1828
[7]   Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery [J].
Hebert, MF .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 27 (2-3) :201-214
[8]   Functional polymorphisms of the human multidrug-resistance gene:: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J].
Hoffmeyer, S ;
Burk, O ;
von Richter, O ;
Arnold, HP ;
Brockmöller, J ;
Johne, A ;
Cascorbi, I ;
Gerloff, T ;
Roots, I ;
Eichelbaum, M ;
Brinkmann, U .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3473-3478
[9]   Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene [J].
Johne, A ;
Köpke, K ;
Gerloff, T ;
Mai, I ;
Rietbrock, S ;
Meisel, C ;
Hoffmeyer, S ;
Kerb, R ;
Fromm, MF ;
Brinkmann, U ;
Eichelbaum, M ;
Brockmöller, J ;
Cascorbi, I ;
Roots, I .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (05) :584-594
[10]   Monitoring cyclosporin in blood:: Between-assay differences at trough and 2 hours post-dose (C2) [J].
Johnston, A ;
Chusney, G ;
Schütz, E ;
Oellerich, M ;
Lee, TD ;
Holt, DW .
THERAPEUTIC DRUG MONITORING, 2003, 25 (02) :167-173